(R)-7-methoxy-2-(n-propylamino)tetralin | 161873-84-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: (R)-7-methoxy-2-(n-propylamino)tetralin
• 英文别名: (R)-7-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine；(7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)propylamine；(R)-(7-methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine；((R)-7-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-amine；(2R)-7-methoxy-N-propyl-1,2,3,4-tetrahydronaphthalen-2-amine
• CAS: 161873-84-3
• 化学式: C₁₄H₂₁NO
• 分子量: 219.327
• InChiKey: RMRODALMKPMZFW-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-7-methoxy-2-(n-propylamino)tetralin 在 氢溴酸 作用下， 反应 2.0h， 以79%的产率得到(R)-(+)-7-hydroxy-2-(n-propylamino)tetralin hydrobromide
  参考文献：
  名称：

  Sonesson; Barf; Nilsson, Journal of Medicinal Chemistry, 1995, vol. 38, # 8, p. 1319 - 1329

  摘要：

  DOI：
• 作为产物：
  描述：

  (7-甲氧基-1,2,3,4-四氢-萘-2-基)-丙基-胺 生成 (R)-7-methoxy-2-(n-propylamino)tetralin
  参考文献：
  名称：

  Sonesson; Barf; Nilsson, Journal of Medicinal Chemistry, 1995, vol. 38, # 8, p. 1319 - 1329

  摘要：

  DOI：

文献信息

• 4-PIPERIDINYL ALKYL AMINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS
  申请人：——

  公开号：US20030162780A1

  公开（公告）日：2003-08-28

  This invention relates to compounds which are generally muscarinic receptor antagonists and which are represented by Formula I: 1 wherein p, R 1 , R 2 , R 3 and A are as defined in the specification, or individual isomers, racemic or non-racemic mixtures of isomers, or acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use and preparation as therapeutic drugs.

  本发明涉及一般为毒蕈碱受体拮抗剂的化合物，这些化合物由通式I表示： 1 其中p、R1、R2、R3和A如说明书中所定义，或为单个异构体、消旋或非消旋异构体混合物，或为其可接受的盐或溶剂合物。本发明还涉及含有此类化合物的药物组合物，以及将其作为治疗药物使用和制备的方法。
• Resolved monophenolic 2-aminotetralins and 1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines: structural and stereochemical considerations for centrally acting pre- and postsynaptic dopamine-receptor agonists
  作者：Haakan Wikstroem、Bengt Andersson、Domingo Sanchez、Per Lindberg、Lars Erik Arvidsson、Anette M. Johansson、J. Lars G. Nilsson、Kjell Svensson、Stephan Hjorth、Arvid Carlsson

  DOI：10.1021/jm00380a012

  日期：1985.2

  centrally acting dopamine (DA) agonists acting on both pre- and postsynaptic DA receptors. The compounds resolved are 5- and 7-hydroxy-2-(di-n-propylamino)tetralin and cis- and trans-7-hydroxy-4-n-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo [f]quinoline. By the superimposition of the structures of the more active enantiomers of these compounds with those of known dopaminergic agonists, apomorphine and ergolines

  揭示了作用在突触前和突触后DA受体上的中枢作用多巴胺（DA）激动剂的详细结构-活性关系。解析出的化合物为5-和7-羟基-2-（二-正丙基氨基）四氢萘林和顺-和反7-羟基-4-正丙基-1,2,3,4,4a，5,6 ，10b-八氢苯并[f]喹啉。通过将这些化合物的更具活性的对映异构体的结构与已知的多巴胺能激动剂，阿扑吗啡和麦角灵重叠，可以提出一种新的DA受体模型，作为当前DA受体理论的产物。该受体模型最重要的概念之一是强调多巴胺能化合物的N取代基可能占据的位置。这些位置中的一个在空间上定义得很好，而另一个方向在空间上不太重要。该模型已被用来解释某些先前报道的结构缺乏多巴胺能活性，还用于预测新型结构的特性，包括固有手性，该结构应对DA受体具有活性。希望这种启发式DA受体模型将导致发现更多选择性和有效药理学工具，最终可能导致开发用于治疗中枢神经系统多巴胺能功能疾病的治疗剂。
• 4-piperidinyl alkyl amine derivatives as muscarinic receptor antagonists
  申请人：——

  公开号：US20040092554A1

  公开（公告）日：2004-05-13

  This invention relates to compounds which are generally muscarinic receptor antagonists and which are represented by Formula I: 1 wherein p, R 1 , R 2 , R 3 and A are as defined in the specification, or individual isomers, racemic or non-racemic mixtures of isomers, or acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds and methods for their use and preparation as therapeutic drugs.

  本发明涉及一般上为肌肉型受体拮抗剂的化合物，其由式I表示：1其中p，R1，R2，R3和A如规范中所定义，或其单一异构体，混合异构体，或其可接受的盐或溶剂化物。本发明还涉及包含这样的化合物的制药组合物以及作为治疗药物使用和制备的方法。
• BIFUNCTIONAL/POLYFUNCTIONAL DOPAMINE D2/D3 AGONIST AS NEUROPROTECTIVE AGENTS FOR TREATMENT OF NEURODEGENERATIVE DISEASES
  申请人：Dutta Aloke K.

  公开号：US20120108815A1

  公开（公告）日：2012-05-03

  A precursor for the deposition of a thin film by atomic layer deposition is provided. The compound has the formula M x L y where M is a metal and L is an amidrazone-derived ligand or an amidate-derived ligand. A process of forming a thin film using the precursors is also provided.

  提供了一种用于原子层沉积薄膜的前体。该化合物具有MxLy的公式，其中M是金属，L是来自酰胺肼衍生的配体或酰胺酸衍生的配体。还提供了使用前体形成薄膜的过程。
• Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and Its Analogues as Highly Potent Dopamine D2/D3 Agonists and as Iron Chelator: In Vivo Activity Indicates Potential Application in Symptomatic and Neuroprotective Therapy for Parkinson’s Disease
  作者：Balaram Ghosh、Tamara Antonio、Maarten E. A. Reith、Aloke K. Dutta

  DOI：10.1021/jm901618d

  日期：2010.3.11

  The role of iron in the pathogenesis of Parkinson's disease (PD) has been implicated strongly because of generation of oxidative stress leading to dopamine cell death. In our overall goal to develop bifunctional/multifunctional drugs, we designed dopamine D2/D3 agonist molecules with a capacity to bind to iron. Binding assays were carried out with HEK-293 cells expressing either D2 or D3 receptor with tritiated spiperone to evaluate inhibition constants (K-i). Functional activity of selected compounds was carried out with GTP gamma S binding assay. SAR results identified compounds (+)-19a and (-)-19b as two Potent agonists for both D2 and D3 receptors (EC50 (GTP gamma S); D2 = 4.51 and 1.69 nM and D3 = 1.58 and 0.74 nM for (-)-19b and (+)-19a, respectively). In vitro complexation Studies with 19b demonstrated efficient chelation with iron. Furthermore, the deoxyribose assay with 19b demonstrated potent antioxidant activity. In PD animal model study, (-)-19b exhibited potent in vivo activity in reversing locomotor activity in reserpinized rats and also in producing potent rotational activity in 6-OHDA lesioned rats. This reports initial development of unique lead molecules that might find potential use in Symptomatic and neuroprotective treatment of PD.